Current Issue : April - June Volume : 2016 Issue Number : 2 Articles : 5 Articles
Background. Survival after liver resection for HCC is compromised by a high rate of intrahepatic recurrence. Adjuvant treatment\nwith a single, postoperative dose of intra-arterial I131 lipiodol has shown promise, as a means of prolonging disease-free survival\n(DFS).Methodology.DFS and overall survival (OS) after a single dose of postoperative I131 lipiodol were compared to liver resection\nalone, for treatment of hepatocellular carcinoma (HCC). Data were collected retrospectively for patients who had a curative\nresection for HCC between December 1993 and September 2011. Seventy-two patients were given I131 lipiodol after surgery and\n70 patients had surgery alone. Results.The DFS at 1, 3, and 5 years was 72%, 43%, and 26% in the surgery group and 70%, 39%, and\n29% in the adjuvant I131 lipiodol group (...
Purpose. The association between transarterial chemoembolization- (TACE-) induced HCC tumor necrosis measured by the\nmodified Response Evaluation Criteria In Solid Tumors (mRECIST) and patient survival is poorly defined. We hypothesize\nthat survival will be superior in HCC patients with increased TACE-induced tumor necrosis. Materials and Methods. TACE\ninterventionswere retrospectively reviewed. Tumor response was quantified via dichotomized (responders and nonresponders) and\nthe four defined mRECIST categories. Results. Median survival following TACE was significantly greater in responders compared\nto nonresponders (20.8 months versus 14.9 months, ...
Cancer is a major disease worldwide. Despite progress in cancer therapy, conventional\ncytotoxic therapies lead to unsatisfactory long-term survival, mainly related to development of\ndrug resistance by tumor cells and toxicity towards normal cells. n-3 polyunsaturated fatty acids\n(PUFAs), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), can exert anti-neoplastic\nactivity by inducing apoptotic cell death in human cancer cells either alone or in combination\nwith conventional therapies. Indeed, n-3 PUFAs potentially increase the sensitivity of tumor cells\nto conventional therapies, possibly improving their efficacy especially against cancers resistant\nto treatment. Moreover, in contrast to traditional therapies, n-3 PUFAs appear to cause selective\ncytotoxicity towards cancer cells with little or no toxicity on normal cells. This review focuses on\nstudies investigating the cytotoxic activity of n-3 PUFAs against cancer cells via apoptosis, analyzing\nthe molecular mechanisms underlying this effective and selective activity. Here, we highlight the\nmultiple molecules potentially targeted by n-3 PUFAs to trigger cancer cell apoptosis. This analysis\ncan allow a better comprehension of the potential cytotoxic therapeutic role of n-3 PUFAs against\ncancer, providing specific information and support to design future pre-clinical and clinical studies\nfor a better use of n-3 PUFAs in cancer therapy, mainly combinational therapy...
PC (pancreatic cancer) is the fourth most common cause of death due to cancer worldwide. The incidence and mortality rates\nhave been increasing year by year worldwide, and this review has analyzed the most recent incidence and mortality data for\npancreatic cancer occurrence in China. Several possible risk factors have been discussed here, involving known established risk\nfactors and novel possible risk factors. The development of this cancer is a stepwise progression through intraepithelial neoplasia to\ncarcinoma.Though early and accurate diagnosis is promising based on a combination of recent techniques including tumor markers\nand imaging modalities, lacking early clinical symptoms makes the diagnosis late. Correct staging is critical because treatment\nis generally based on this parameter. Treatment options have improved throughout the last decades. However, surgical excision\nremains the primary therapy and efficacy of conventional chemoradiotherapy for PC is limited. Recently, some novel new therapies\nhave been developed and will be applied in clinics soon. This review will provide an overview of pancreatic cancer, including an\nunderstanding of the developments and controversies....
Introduction. Recombinant human thyroid stimulating hormone (rhTSH) is approved for preparation of thyroid remnant ablation\nwith radioactive iodine (RAI) in low risk patients with well differentiated thyroid cancer (DTC).We studied the safety and efficacy\nof rhTSH preparation for RAI treatment of thyroid cancer patients with nodalmetastatic disease. Methods. A retrospective analysis\nwas performed on 108 patients with histopathologically confirmed nodal metastatic DTC, treated with initial RAI between January\n1, 2000, and December 31, 2007. Within this selected group, 31 and 42 patients were prepared for initial and all subsequent RAI\ntreatments by either thyroid hormone withdrawal (THW) or rhTSH protocols and were followed up for at least 3 years. Results. The\nresponse to initial treatment, classified as excellent, acceptable, or incomplete, was not different between the rhTSH group (57%,\n21%, and 21%, resp.) and the THW group (39%, 13%, and 48%, resp.; ...
Loading....